^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19-targeted CAR-T immunotherapy

    Related drugs:
    1d
    IVIG for Infection Prevention After CAR-T-Cell Therapy (clinicaltrials.gov)
    P2, N=150, Recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: Jul 2027 --> Jul 2028
    Trial primary completion date
    1d
    AAAV0505: A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=6, Suspended, Columbia University | Recruiting --> Suspended
    Trial suspension
    |
    cyclophosphamide • NKX019
    1d
    SZ4601: CAR-T Cell Therapy Targeting to CD19 for R/R ALL (clinicaltrials.gov)
    P1/2, N=196, Recruiting, The First Affiliated Hospital of Soochow University | Active, not recruiting --> Recruiting | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Aug 2024 --> Aug 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    1d
    A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases (clinicaltrials.gov)
    P1, N=52, Recruiting, Kite, A Gilead Company | Not yet recruiting --> Recruiting
    Enrollment open • Pan tumor
    |
    LRP4 (LDL Receptor Related Protein 4)
    |
    cyclophosphamide • fludarabine IV • KITE-363
    1d
    A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, Genentech, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide • fludarabine IV • RG6540
    2d
    CAR-T+ASCT: CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors. (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Zhejiang Cancer Hospital
    New P2 trial
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    TP53 mutation
    |
    cytarabine • Yescarta (axicabtagene ciloleucel) • carmustine • melphalan
    5d
    Case Report: Transverse myelitis following CAR-T cell therapy for post-transplant lymphoproliferative disorder. (PubMed, Front Immunol)
    We report a case of severe, irreversible transverse myelitis following CD19-directed CAR-T cell therapy (axicabtagene ciloleucel) for refractory post-transplant lymphoproliferative disorder (PTLD) in a young female lung-transplant recipient...We further address diagnostic challenges, and review current management strategies such as corticosteroids, IL-1 blockade, and IL-6 neutralization. This report underscores the need for heightened vigilance, early imaging, and systematic reporting to improve prevention and treatment of this rare but severe CAR-T-related neurotoxicity.
    Journal
    |
    IL6 (Interleukin 6) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CCL2 (Chemokine (C-C motif) ligand 2) • IL18 (Interleukin 18)
    |
    Yescarta (axicabtagene ciloleucel)
    6d
    MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, Miltenyi Biomedicine GmbH | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    zorpocabtagene autoleucel (MB-CART 19.1)
    6d
    Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, University of Michigan Rogel Cancer Center
    New P1 trial
    |
    pomalidomide
    6d
    CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants (clinicaltrials.gov)
    P1, N=12, Recruiting, Tongji Hospital | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    IFNG (Interferon, gamma) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • SDC1 (Syndecan 1) • IL13 (Interleukin 13) • IL4 (Interleukin 4)
    |
    AZD0120
    7d
    Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma. (PubMed, Br J Haematol)
    We retrospectively analysed LBCL patients in the Japanese nationwide registry who underwent CD19 CAR-T-cell therapy between 2019 and 2024...Decreased eGFR, a surrogate of host renal reserve, with elevated ferritin, CRP and LDH emerged as predictors of high-grade CRS. The CRS-PRE may facilitate risk-adapted monitoring and intervention in clinical practice.
    Journal
    |
    CRP (C-reactive protein)
    |
    CD19.CAR-T
    7d
    APHP241013: PREV-CART - A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiotic prophylaxis (AP) in patients treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B cell acute lymphoblastic leukemia or a B cell lymphoma (2025-521571-30-00)
    P2/3, N=228, Not yet recruiting, Assistance Publique Hopitaux De Paris
    New P2/3 trial